CIM
CORT icon

Chiron Investment Management’s Corcept Therapeutics CORT Stock Holding History

Chiron Investment Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,380
Closed -$60K – 79
2024
Q1 		$60K Buy
2,380
+1,026
+76% +$24.2K 0.03% 100
2023
Q4 		$44K Buy
+1,354
New +$37.2K 0.02% 61
2023
Q1 		– Sell
-5,572
Closed -$113K – 138
2022
Q4 		$113K Buy
5,572
+1,615
+41% +$40.5K 0.03% 103
2022
Q3 		$101K Buy
+3,957
New +$106K 0.02% 117

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Chiron Investment Management's CORT Position: Q2 2024 in Review

Chiron Investment Management sold out of Corcept Therapeutics (CORT) in Q2 2024, closing a stake of 2,380 shares — an estimated $60K sold.

Chiron Investment Management first reported a position in CORT in Q3 2022 and held it in 4 quarters. The position peaked at $113K in Q4 2022. 286 funds tracked by Wall St. Rank hold CORT as of Q2 2024.

  • Chiron Investment Management reported no remaining Corcept Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Chiron Investment Management sold 2,380 Corcept Therapeutics shares in Q2 2024, an estimated $60K.
  • Chiron Investment Management first reported a position in Corcept Therapeutics in Q3 2022 and held it in 4 quarters.
  • Chiron Investment Management's Corcept Therapeutics position peaked at $113K in Q4 2022.
  • 286 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2024.

Based on Chiron Investment Management's 13F filing for Q2 2024, filed 13 Aug 2024.